485 related articles for article (PubMed ID: 23770179)
1. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.
Ballantyne CM; Davidson MH; Macdougall DE; Bays HE; Dicarlo LA; Rosenberg NL; Margulies J; Newton RS
J Am Coll Cardiol; 2013 Sep; 62(13):1154-62. PubMed ID: 23770179
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus.
Gutierrez MJ; Rosenberg NL; Macdougall DE; Hanselman JC; Margulies JR; Strange P; Milad MA; McBride SJ; Newton RS
Arterioscler Thromb Vasc Biol; 2014 Mar; 34(3):676-83. PubMed ID: 24385236
[TBL] [Abstract][Full Text] [Related]
3. ETC-1002: a future option for lipid disorders?
Nikolic D; Mikhailidis DP; Davidson MH; Rizzo M; Banach M
Atherosclerosis; 2014 Dec; 237(2):705-10. PubMed ID: 25463109
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
Feldman T; Davidson M; Shah A; Maccubbin D; Meehan A; Zakson M; Tribble D; Veltri E; Mitchel Y
Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
Bays HE; Ose L; Fraser N; Tribble DL; Quinto K; Reyes R; Johnson-Levonas AO; Sapre A; Donahue SR;
Clin Ther; 2004 Nov; 26(11):1758-73. PubMed ID: 15639688
[TBL] [Abstract][Full Text] [Related]
6. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.
Ose L; Shah A; Davies MJ; Rotonda J; Maccubbin D; Tribble D; Veltri E; Mitchel Y
Curr Med Res Opin; 2006 May; 22(5):823-35. PubMed ID: 16709304
[TBL] [Abstract][Full Text] [Related]
7. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial.
Lewis JH; Mortensen ME; Zweig S; Fusco MJ; Medoff JR; Belder R;
Hepatology; 2007 Nov; 46(5):1453-63. PubMed ID: 17668878
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance.
Laufs U; Banach M; Mancini GBJ; Gaudet D; Bloedon LT; Sterling LR; Kelly S; Stroes ESG
J Am Heart Assoc; 2019 Apr; 8(7):e011662. PubMed ID: 30922146
[TBL] [Abstract][Full Text] [Related]
10. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance.
Thompson PD; Rubino J; Janik MJ; MacDougall DE; McBride SJ; Margulies JR; Newton RS
J Clin Lipidol; 2015; 9(3):295-304. PubMed ID: 26073387
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
Roth EM; McKenney JM; Kelly MT; Setze CM; Carlson DM; Gold A; Stolzenbach JC; Williams LA; Jones PH
Am J Cardiovasc Drugs; 2010; 10(3):175-86. PubMed ID: 20524719
[TBL] [Abstract][Full Text] [Related]
13. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe.
Bays H; Rhyne J; Abby S; Lai YL; Jones M
Curr Med Res Opin; 2006 Nov; 22(11):2191-200. PubMed ID: 17076980
[TBL] [Abstract][Full Text] [Related]
14. Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.
Rubino J; MacDougall DE; Sterling LR; Kelly SE; McKenney JM; Lalwani ND
J Clin Lipidol; 2021; 15(4):593-601. PubMed ID: 34172394
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study.
Masana L; Mata P; Gagné C; Sirah W; Cho M; Johnson-Levonas AO; Meehan A; Troxell JK; Gumbiner B;
Clin Ther; 2005 Feb; 27(2):174-84. PubMed ID: 15811480
[TBL] [Abstract][Full Text] [Related]
16. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
[TBL] [Abstract][Full Text] [Related]
17. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
[TBL] [Abstract][Full Text] [Related]
18. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
19. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Ferdinand KC; Davidson MH; Kelly MT; Setze CM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
[TBL] [Abstract][Full Text] [Related]
20. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
Ballantyne CM; Laufs U; Ray KK; Leiter LA; Bays HE; Goldberg AC; Stroes ES; MacDougall D; Zhao X; Catapano AL
Eur J Prev Cardiol; 2020 Apr; 27(6):593-603. PubMed ID: 31357887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]